137 related articles for article (PubMed ID: 23911192)
1. Diabetes device reimbursement in the EU-5.
Schäfer E; Schnell G; Bobáková T
J Diabetes Sci Technol; 2013 Jul; 7(4):1084-92. PubMed ID: 23911192
[TBL] [Abstract][Full Text] [Related]
2. Obtaining reimbursement in France and Italy for new diabetes products.
Schaefer E; Schnell G; Sonsalla J
J Diabetes Sci Technol; 2015 Jan; 9(1):156-61. PubMed ID: 25550411
[TBL] [Abstract][Full Text] [Related]
3. Reimbursement Pathways for New Diabetes Technologies in Europe: Top-Down Versus Bottom-Up.
Seidel D; Boggio Mesnil F; Caruso A
J Diabetes Sci Technol; 2019 Jan; 13(1):118-122. PubMed ID: 30033750
[TBL] [Abstract][Full Text] [Related]
4. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
5. Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review.
Beck A; Retèl VP; Bhairosing PA; van den Brekel M; van Harten WH
Health Policy; 2019 Dec; 123(12):1185-1198. PubMed ID: 31718855
[TBL] [Abstract][Full Text] [Related]
6. Considerations for an institution for evaluation of diabetes technology devices to improve their quality in the European Union.
Heinemann L; Freckmann G; Koschinsky T
J Diabetes Sci Technol; 2013 Mar; 7(2):542-7. PubMed ID: 23567012
[TBL] [Abstract][Full Text] [Related]
7. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
8. Balancing adoption and affordability of medical devices in Europe.
Schreyögg J; Bäumler M; Busse R
Health Policy; 2009 Oct; 92(2-3):218-24. PubMed ID: 19410326
[TBL] [Abstract][Full Text] [Related]
9. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
10. Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator-Comparison of Five European Healthcare Systems.
Fritzen K; Basinska K; Stautner C; Braun KF; Rubio-Almanza M; Nicolucci A; Kennon B; Vergès B; Hosny Y; Schnell O
J Diabetes Sci Technol; 2020 Mar; 14(2):262-270. PubMed ID: 31387385
[TBL] [Abstract][Full Text] [Related]
11. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
Martelli N; van den Brink H
Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
[TBL] [Abstract][Full Text] [Related]
12. Reimbursement pricing for new medical devices in Japan: Is the evaluation of innovation appropriate?
Tamura M; Nakano S; Sugahara T
Int J Health Plann Manage; 2019 Apr; 34(2):583-593. PubMed ID: 30549085
[TBL] [Abstract][Full Text] [Related]
13. Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective.
Sumnik Z; Szypowska A; Iotova V; Bratina N; Cherubini V; Forsander G; Jali S; Raposo JF; Stipančic G; Vazeou A; Veeze H; Lange K;
Pediatr Diabetes; 2019 Jun; 20(4):434-443. PubMed ID: 30773756
[TBL] [Abstract][Full Text] [Related]
14. Patient access to voice prostheses and heat and moisture exchangers: Factors influencing physician's prescription and reimbursement in eight European countries.
Beck ACC; Retèl VP; van den Brekel MWM; van Harten WH
Oral Oncol; 2019 Apr; 91():56-64. PubMed ID: 30926063
[TBL] [Abstract][Full Text] [Related]
15. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
16. How to value technological innovation: a proposal for determining relative clinical value.
Ladabaum U; Brill JV; Sonnenberg A; Shaheen NJ; Inadomi J; Wilcox CM; Park WG; Hur C; Pasricha PJ
Gastroenterology; 2013 Jan; 144(1):5-8. PubMed ID: 23153872
[No Abstract] [Full Text] [Related]
17. Has the European union achieved a single pharmaceutical market?
Timur A; Picone G; DeSimone J
Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
[TBL] [Abstract][Full Text] [Related]
18. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
Gress S; Niebuhr D; May U; Wasem J
Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
[TBL] [Abstract][Full Text] [Related]
19. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
20. The healthcare systems and provision of oral healthcare in European Union member states. Part 10: comparison of systems and with the United Kingdom.
Sinclair E; Eaton KA; Widström E
Br Dent J; 2019 Aug; 227(4):305-310. PubMed ID: 31444448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
